GLP-1 Receptor Agonists mimic the native incretin hormone GLP-1, which enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on the brain to reduce appetite and food intake. These combined actions lead to substantial weight loss and improved glycemic control, which are foundational for extending healthspan by mitigating the progression of metabolic diseases.
Verdict
Highly effective for metabolic health and weight loss, but requires medical supervision.
HEALTHSPAN IMPACT
Foundational
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$900 - $1500
Protocol
- Typically administered via weekly subcutaneous injections, with doses titrated up over several months to manage side effects.
- Oral formulations are available for some agents and are typically taken daily.
Flags
- Common side effects include nausea, vomiting, diarrhea, and constipation, especially during dose escalation.
- Risk of pancreatitis, gallbladder disease, and gastroparesis (stomach paralysis) has been reported.
- Boxed warning for risk of thyroid C-cell tumors based on rodent studies; relevance to humans is uncertain.
- Potential for significant loss of lean muscle mass alongside fat mass, requiring mitigation strategies like resistance training.
- Rapid weight regain is common after discontinuation of the medication.
- Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.